skip to content
5i Free Trial 300x250
Detailed Quote
5i Report

Review of Cipher Pharmaceuticals

AUG 16, 2018 - Dermatology pharmaceutical business with recent acquisition and growth in product pipeline, with some mixed results in the past. Coverage dropped until some visibility emerges.

Download Report
Company Profile
Interactive Chart
Key Ratios
Top Banner 5i Free Trial
Earnings
Analyst Recommendations
5i Recent Questions

Q: Cipher's quarterly report highlights transitions and strategic positioning for long term growth, also debt reduction. Their list of 2018 year end highlights appears impressive but does it read that way to you? This company looks busy for their size but what significants do you take from the list of 2019 anticipated milestones? Would you dip a toe in here? Finally how similar are CPH and GUD in strategic growth plans?

Read Answer Asked by Gerry on March 21, 2019
Insiders
CMS Buy Now
Share Information
News and Media